

By: Bucy, Oliverson, Pierson, Romero, et al.

H.B. No. 4014

A BILL TO BE ENTITLED

AN ACT

relating to a study on the use of psychedelic therapies in the treatment of certain conditions.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:

SECTION 1. (a) In this Act:

(1) "Commission" means the Health and Human Services Commission.

(2) "Psychedelic therapies" means the use of 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, or ketamine to treat mental health or other medical conditions.

(b) The commission, in consultation with Baylor College of Medicine and the Center for Psychedelic Research and Therapy at Dell Medical School at The University of Texas at Austin, shall conduct a study on the use of psychedelic therapies for treatment of post-traumatic stress disorder, depression, and other co-occurring conditions.

(c) In conducting the study, the commission shall:

(1) review clinical trials on the efficacy of using psychedelic therapies in the treatment of post-traumatic stress disorder, depression, and other co-occurring conditions;

(2) review current literature regarding the use of psychedelic therapies in the treatment of post-traumatic stress disorder, depression, and other co-occurring conditions;

(3) review actions of the United States Food and Drug

1 Administration regarding psychedelic therapies for treatment of
2 post-traumatic stress disorder, depression, and other co-occurring
3 conditions;

4 (4) evaluate treatment guidelines for use of
5 psychedelic therapies to treat post-traumatic stress disorder,
6 depression, and other co-occurring conditions and recommend
7 guidelines and best practices for providers; and

8 (5) evaluate patient access to current treatment for
9 post-traumatic stress disorder, depression, and other co-occurring
10 conditions and recommend legislative or other actions necessary to
11 ensure patient access to psychedelic therapies following approval
12 by the United States Food and Drug Administration, including
13 considerations of provider availability, affordability,
14 accessibility, training and licensure, and other regulatory
15 requirements.

16 (d) In addition to any money appropriated by the
17 legislature, the commission may solicit and accept federal funds
18 and gifts, grants, or donations from any source to administer and
19 finance the study conducted under this section.

20 (e) Not later than December 1, 2026, the commission shall
21 submit to the governor, the lieutenant governor, the speaker of the
22 house of representatives, and the chair of the standing committee
23 of each house of the legislature with primary jurisdiction over the
24 commission a written report that includes:

25 (1) the results of the study conducted under this
26 section; and

27 (2) any recommendations for legislative or other

1 action necessary to ensure patient access to psychedelic therapies
2 for treatment of post-traumatic stress disorder, depression, and
3 other co-occurring conditions after those therapies are approved by
4 the United States Food and Drug Administration.

5 (f) This Act expires September 1, 2027.

6 SECTION 2. The Health and Human Services Commission is
7 required to implement a provision of this Act only if the
8 legislature appropriates money specifically for that purpose. If
9 the legislature does not appropriate money specifically for that
10 purpose, the commission may, but is not required to, implement a
11 provision of this Act using other money available for that purpose.

12 SECTION 3. This Act takes effect September 1, 2025.